Cargando…
Successful treatment with atezolizumab in a haemodialysis patient with large cell neuroendocrine carcinoma
In this report, a modified regimen based on IMpower 133 (carboplatin + etoposide + atezolizumab) was administered to a patient diagnosed with large cell neuroendocrine carcinoma (LCNEC) who was concurrently undergoing haemodialysis. Adverse events led to the discontinuation of carboplatin and etopos...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356775/ https://www.ncbi.nlm.nih.gov/pubmed/37484711 http://dx.doi.org/10.1002/rcr2.1193 |